Abstract
Reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is a membrane-anchored glycoprotein that negatively regulates the activities of matrix metalloproteinases (MMPs) and inhibits tumor invasion, metastasis, and angiogenesis. RECK is essential for normal development and is a key mediator of tissue remodeling and stabilization of tissue architechture. Downregulation of RECK documented in a wide range of malignant neoplasms correlates with poor prognosis, and tumor metastasis. The RECK gene is a common negative target for oncogenic signals that act on the Sp1-binding site of the RECK promoter. Both natural and synthetic agents have been identified as upregulators of RECK. Several strategies have been proposed to enhance RECK expression including forced expression of RECK, use of mimetics, recombinant peptides, microRNA antagonists, and gene therapy. Upregulation of RECK could be a valuable therapeutic option to improve prognosis and block tumor progression. This review addresses the potential value of RECK as a prognostic marker and as a molecular target for cancer therapy.
Keywords: Angiogenesis, Histone deacetylase, Invasion, Matrix metalloproteinases, RECK, Sp1 protein, Tissue inhibitor of matrix metalloproteinases, cytotrophoblasts, syncytiotrophoblasts, glycosylphosphatidylinositol.
Anti-Cancer Agents in Medicinal Chemistry
Title:RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Volume: 12 Issue: 7
Author(s): Siddavaram Nagini
Affiliation:
Keywords: Angiogenesis, Histone deacetylase, Invasion, Matrix metalloproteinases, RECK, Sp1 protein, Tissue inhibitor of matrix metalloproteinases, cytotrophoblasts, syncytiotrophoblasts, glycosylphosphatidylinositol.
Abstract: Reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is a membrane-anchored glycoprotein that negatively regulates the activities of matrix metalloproteinases (MMPs) and inhibits tumor invasion, metastasis, and angiogenesis. RECK is essential for normal development and is a key mediator of tissue remodeling and stabilization of tissue architechture. Downregulation of RECK documented in a wide range of malignant neoplasms correlates with poor prognosis, and tumor metastasis. The RECK gene is a common negative target for oncogenic signals that act on the Sp1-binding site of the RECK promoter. Both natural and synthetic agents have been identified as upregulators of RECK. Several strategies have been proposed to enhance RECK expression including forced expression of RECK, use of mimetics, recombinant peptides, microRNA antagonists, and gene therapy. Upregulation of RECK could be a valuable therapeutic option to improve prognosis and block tumor progression. This review addresses the potential value of RECK as a prognostic marker and as a molecular target for cancer therapy.
Export Options
About this article
Cite this article as:
Nagini Siddavaram, RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review), Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/187152012802650237
DOI https://dx.doi.org/10.2174/187152012802650237 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Circulating Endothelial Progenitor Cells in Tumor Angiogenesis
Current Stem Cell Research & Therapy Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Current Medicinal Chemistry Brain MR Image Classification for Glioma Tumor detection using Deep Convolutional Neural Network Features
Current Medical Imaging Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Approaches to Improve Cellular Retention of Radiohalogen Labels Delivered by Internalising Tumour-Targeting Proteins and Peptides
Current Medicinal Chemistry Lactate in Solid Malignant Tumors: Potential Basis of a Metabolic Classification in Clinical Oncology
Current Medicinal Chemistry Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) A Comparative Study Between the Leaf and Flowers of Some Asteraceae Plants With Respect to Their Antioxidant Activity Compounds
Current Nutrition & Food Science P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Role of ATP-Binding Cassette Transporter Proteins in CNS Tumors: Resistance- Based Perspectives and Clinical Updates
Current Pharmaceutical Design Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Current Pharmaceutical Design Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Lipid Metabolism and Mitochondria: Cross Talk in Cancer
Current Drug Targets